Program
Atropine
Also written as “Atropine Sulfate”, “Low dose atropine sulfate eye drops” and “atropine sulfate”.
Its studies are mostly in Myopia · Myopia, Degenerative · Insulin Resistance · Rhinitis, Allergic, Seasonal, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hai Yen Eye Care | 20 open or running | phase 1since Sep 27, 2018 | Sep 27, 2018 | none ahead |
| Laboratorios Sophia S.A de C.V. | 20 open or running | phase 1since Mar 23, 2022 | Mar 23, 2022 | none ahead |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | 22 open or running | phase 3since Jan 5, 2024 | Jan 5, 2024 | none ahead |
| cloudbreak-therapeutics-llc | 10 open or running | phase 2since May 5, 2021 | May 5, 2021 | none ahead |
| Eyenovia | 10 open or running | phase 3since May 7, 2019 | May 7, 2019 | none ahead |
| IDB VisionCare SDN BHD | 11 open or running | phase 3since Sep 16, 2025 | Sep 16, 2025 | Sep 2027phase 3 · NCT07329777 |
| Kubota Pharmaceutical | 11 open or running | no phasesince Aug 26, 2023 | Aug 26, 2023 | none ahead |
| magna-pharmaceuticals-inc | 10 open or running | phase 2since Feb 26, 2014 | Feb 26, 2014 | none ahead |
| microdose-defense-products-l-l-c | 10 open or running | phase 1since Jul 22, 2009 | Jul 22, 2009 | none ahead |
| Ocumension Therapeutics (Suzhou) | 10 open or running | phase 3since Nov 18, 2024 | Nov 18, 2024 | none ahead |
| Ocus Innovation Ireland | 11 open or running | phase 3since May 23, 2025 | May 23, 2025 | Dec 31, 2027phase 3 · NCT07028827 |
| scimar-ltd | 10 open or running | no phasesince Oct 29, 2020 | Oct 29, 2020 | none ahead |
| Sydnexis | 10 open or running | phase 3since Apr 12, 2019 | Apr 12, 2019 | none ahead |
| Zhaoke (Hong Kong) Ophthalmology Pharmaceutical | 11 open or running | phase 1since Apr 23, 2023 | Apr 23, 2023 | none ahead |
- Named in jiangsu hengrui medicine’s own pipeline as
Atropine eye drops
, phase 4, as of Jul 31, 2026 (source).
Also a collaborator on its studies: euromed-pharma-services-srl, novotech-australia-pty-limited, source-nutraceutical-inc and brien-holden-vision.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 22, 2009.
- Sep 27, 2018Hai Yen Eye Care's first study: phase 1 study in MyopiaNew to Hai Yen Eye CareHai Yen Eye Care · NCT03690414 · 52 enrolled · Vietnam
- Oct 5, 2018Phase 1 study in MyopiaHai Yen Eye Care · NCT03699423 · 58 enrolled · Vietnam
- Apr 12, 2019Sydnexis's first study: phase 3 study in MyopiaNew to SydnexisSydnexis · NCT03918915 · 852 enrolled · United States, Austria, Slovakia
- May 7, 2019Eyenovia's first study: phase 3 study in MyopiaNew to EyenoviaEyenovia · NCT03942419 · 438 enrolled · United States
- Oct 29, 2020scimar-ltd's first study: no phase study in Insulin ResistanceNew to scimar-ltdscimar-ltd · NCT04625088 · 24 enrolled · Canada
- May 5, 2021cloudbreak-therapeutics-llc's first study: phase 2 study in Myopia, DegenerativeNew to cloudbreak-therapeutics-llccloudbreak-therapeutics-llc · NCT05372991 · 84 enrolled · Australia
- Mar 23, 2022Laboratorios Sophia S.A de C.V.'s first study: phase 1 study in MyopiaNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT05470881 · 29 enrolled · Mexico
- Jul 28, 2022Phase 1 study in MyopiaLaboratorios Sophia S.A de C.V. · NCT05481489
- Apr 23, 2023Zhaoke (Hong Kong) Ophthalmology Pharmaceutical's first study: phase 1 study in PharmacokineticsNew to Zhaoke (Hong Kong) Ophthalmology PharmaceuticalZhaoke (Hong Kong) Ophthalmology Pharmaceutical · NCT05855018 · 30 planned · China
- Aug 26, 2023Kubota Pharmaceutical's first study: no phase study in MyopiaNew to Kubota PharmaceuticalKubota Pharmaceutical · NCT06034379 · 45 planned · Taiwan
- Jan 5, 2024Zhaoke (Guangzhou) Ophthalmology Pharmaceutical's first studies: 2 phase 3 studies in MyopiaNew to Zhaoke (Guangzhou) Ophthalmology PharmaceuticalZhaoke (Guangzhou) Ophthalmology Pharmaceutical · NCT06209281, NCT06209320
- Nov 18, 2024Ocumension Therapeutics (Suzhou)'s first study: phase 3 study in MyopiaNew to Ocumension Therapeutics (Suzhou)Ocumension Therapeutics (Suzhou) · NCT06697522 · 148 enrolled · China
- May 23, 2025Ocus Innovation Ireland's first study: phase 3 study in MyopiaNew to Ocus Innovation IrelandOcus Innovation Ireland · NCT07028827 · 234 planned · Albania, Italy, Poland and more
- Sep 16, 2025IDB VisionCare SDN BHD's first study: phase 3 study in Myopia ProgressionNew to IDB VisionCare SDN BHDIDB VisionCare SDN BHD · NCT07329777 · 144 planned · Malaysia
Ahead
- Sep 2027Primary completion: phase 3 study in Myopia ProgressionIDB VisionCare SDN BHD · NCT07329777
- Dec 31, 2027Primary completion: phase 3 study in MyopiaOcus Innovation Ireland · NCT07028827
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07329777Myopia Progression · Malaysia | 3 | Recruiting | IDB VisionCare SDN BHD | Sep 2027 | 144 |
| NCT07028827Myopia · Albania, Italy, Poland and more | 3 | Recruiting | Ocus Innovation Ireland | Dec 31, 2027 | 234 |
| NCT06697522Myopia · China | 3 | Completed | Ocumension Therapeutics (Suzhou) | Oct 6, 2023 | 148 |
| NCT06209320Myopia · China | 3 | Active, not recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Mar 21, 2025 | 777 |
| NCT06209281Myopia · China | 3 | Active, not recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Aug 20, 2023 | 526 |
| NCT06034379Myopia · Taiwan | – | Recruiting | Kubota Pharmaceutical | Dec 2025 | 45 |
| NCT05855018Pharmacokinetics · China | 1 | Recruiting | Zhaoke (Hong Kong) Ophthalmology Pharmaceutical | Jun 2023 | 30 |
| NCT05481489Myopia | 1 | Withdrawn | Laboratorios Sophia S.A de C.V. | Mar 31, 2023 | 0 |
| NCT05470881Myopia · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | Dec 26, 2022 | 29 |
| NCT05372991Myopia, Degenerative · Australia | 2 | Completed | cloudbreak-therapeutics-llc | Jan 18, 2023 | 84 |
| NCT04625088Insulin Resistance · Canada | – | Completed | scimar-ltd | Aug 6, 2021 | 24 |
| NCT03942419Myopia · United States | 3 | Terminated | Eyenovia | Oct 31, 2024 | 438 |
| NCT03918915Myopia · United States, Austria, Slovakia | 3 | Completed | Sydnexis | May 2, 2024 | 852 |
| NCT03699423Myopia · Vietnam | 1 | Completed | Hai Yen Eye Care | Apr 30, 2018 | 58 |
| NCT03690414Myopia · Vietnam | 1 | Completed | Hai Yen Eye Care | Feb 2, 2019 | 52 |
| NCT02082054Rhinitis, Allergic, Seasonal · United States | 2 | UNKNOWN | magna-pharmaceuticals-inc | May 2014 | 125 |
| NCT00947596Organophosphate Poisoning · United States | 1 | Completed | microdose-defense-products-l-l-c | Jul 2010 | 18 |
How it is read
Names in the registry
- “Atropine Sulfate”, 3 entries
- “Low dose atropine sulfate eye drops”, 3 entries
- “atropine sulfate”, 2 entries
- “SYD-101 0.01%”, 1 entry
- “SYD-101 0.03%”, 1 entry
Conditions, from the studies’ own filings
- Myopia, 12 studies
- Myopia, Degenerative, 1 study
- Insulin Resistance, 1 study
- Rhinitis, Allergic, Seasonal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.